Peri-implant Bone Formation of Grafted Sites Around Hydrophilic and Non-hydrophilic Dental Implants

NCT ID: NCT06460103

Last Updated: 2024-06-14

Basic Information

• Recruitment Status: NOT_YET_RECRUITING
• Clinical Phase: NA
• Total Enrollment: 70 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2024-07-31
• Study Completion Date: 2027-12-31

Brief Summary

Although bone grafting at the same time as the placement of dental implants is a common procedure in implantology, there are currently no data on the influence of different types of implant surfaces on bone healing, which is crucial for implant stability.

The primary objective of this study is to assess if implant surface properties, i.e. hydrophilicity, affect the osseointegration of the implant in simultaneously augmented bone.

The secondary objective is to assess if implant surface properties, i.e. surface hydrophilicity, may affect the quantity of newly formed bone in the implant in simultaneously augmented bone.

Surface hydrophilicity modification is a well-adapted concept in dental implantology and is clinically well-established.

In this prospective study, all participants will receive a bone graft after extraction. After randomization, one group will receive a provisional SLA surface implant and another group will receive a provisional SLActive surface implant. The same standard surgical procedure will be performed for both groups when the definitive implant will be placed.

The study will run for a total of 3 year, and 35 patients per group will be included.

The Straumann SLA and SLActive implants, Maxgraft allograft and collprotect collagen membranes used in this study are all approved products on the Swiss market.

Detailed Description

The proposed study aims to histometrically investigate the influence of Titanium dental implant surface properties on the peri-implant bone formation in simultaneously bone-augmented implantation sites.

The magnitude of peri-implant bone formation and implant integration in augmented bone are clinically relevant for various clinical success criteria, including, e.g. long-term mechanical and aesthetic stability of load-bearing dental implants. Implant integration in simultaneously augmented bone, i.e. the investigated indication, can be considered critical for the success of approx. 40 to 50 % of all performed dental implant procedures world wide. The investigated subject is believed to be directly clinically relevant.

A common strategy to promote implant osseointegration and long-term implant stability is based on modifying Titanium dental implant surfaces' topographical and physicochemical properties.

The influence of topographical and physicochemical surface properties, including surface energy and hydrophilicity, of dental implants on the rate and extend of osseointegration in native bone has been well described. Also, the physicochemical material characteristics of bone substitutes have been shown to influence the rate of bone formation in augmented sites. Despite this thorough understanding of the individual influences of implant and bone graft properties, the interaction and synergistic properties between Titanium and Titanium Zirconium dental implant surfaces and bone substitutes on dental implant integration and bone formation in augmented sites remain widely undocumented. Investigations on a possible influence of implant surface/bone graft combination on implant osseointegration and peri-implant bone formation remain limited to very defined animal model systems. It is currently unclear if the preclinically observed effects may translate and be valid for human subjects. Consequently, the proposed study hypotheses that implant surface hydrophilicity may influence implant osseointegration and peri-implant bone formation in simultaneously augmented sites is novel, clinically undocumented, whilst highly relevant for the clinical and aesthetic success of a relevant portion of dental implant procedures.

The investigation is planned to be performed in patients displaying single hopeless teeth diagnosed for extraction and replacement by single implants requiring prior bone augmentation at the extraction site. The placement and retrieval of mini-implants are not considered to increase the number or significantly impact the type of planned interventions compared to routine treatment.

Specifically, treatments for the described indication consist of a 2-staged procedure requiring extraction and bone augmentation (first stage) followed by a second procedure for implant placement (second stage). The proposed study's design will be based on the placement of a mini implant in the centre of the extraction site as part of the first augmentation procedure. The mini-implant placement does not affect the treatment plan or outcome. It does not expose the patients to additional risks compared to routine treatment. By contrast, mini-implant placement may help reduce any potential risks for graft displacement of the bone augmentation and may support bone formation within the augmented area.

The second stage procedure will be used to retrieve the mini-implant using a core biopsy trephine instead of preparing the osteotomy by conventional drilling. The resulting osteotomy will be subsequently fine-prepared for the final, permanent implant placement. The required exact placement of the mini-implant at the planned ideal prosthetic position of the final implant can be considered routine, is clinically well-plannable and can be well-controlled as part of the available modern treatment workflows. The treatment sequence and outcome for the patient, i.e. a permanent implant-born restoration, is not expected to be affected by the planned investigation-related intervention, i.e. the placement and retrieval of a mini-implant.

From a parametric and methodological standpoint, histometric analysis can be considered the method of choice to study and quantify bone-to-implant contact and peri-implant bone formation. The patients will be recruited from regular patients diagnosed according to the described indication and scheduled for treatment at the University Hospital of Geneva.

Conditions

Partially Edentulous Maxilla; Partially Edentulous Mandible

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: BASIC_SCIENCE
• Blinding Strategy: SINGLE

Study Groups

"Straumann® Bone Level Tapered SLActive®" mini-implant (hydrophilic surface)

Tooth extraction + "Straumann® Bone Level Tapered, SLActive®" mini-implant placement + bone augmentation (bone graft "maxgraft® cortico-cancellous granules 0.5-2.0mm" and dental membrane "collprotect®membrane")

Group Type: EXPERIMENTAL

Placement of a "Straumann® Bone Level Tapered implant SLActive®" (hydrophilic surface)

Intervention Type: DEVICE

Immediately after tooth extraction, patients will receive a "Straumann® Bone Level Tapered SLActive®" mini-implant at the ideal prosthetic position of the final implant, and bone augmentation using bone graft "maxgraft® " and dental membrane "collprotect®membrane".

The mini-implant will be removed as a core trephine biopsy; the resulting osteotomies will be fine-prepared, and the final permanent implant will be placed after a healing period of 3 weeks post-augmentation.

"Straumann® Bone Level Tapered implants SLA®" mini-implant (hydrophobic surface)

Tooth extraction + "Straumann® Bone Level Tapered , SLA®" mini-implant placement + bone augmentation (bone graft "maxgraft® cortico-cancellous granules 0.5-2.0mm" and dental membrane "collprotect®membrane")

Group Type: ACTIVE_COMPARATOR

Placement of a "Straumann® Bone Level Tapered implant SLA®" (hydrophobic surface)

Intervention Type: DEVICE

Immediately after tooth extraction, patients will receive a "Straumann® Bone Level Tapered SLA®" mini-implant at the ideal prosthetic position of the final implant, and bone augmentation using bone graft "maxgraft® " and dental membrane "collprotect®membrane".

The mini-implant will be removed as a core trephine biopsy; the resulting osteotomies will be fine-prepared, and the final permanent implant will be placed after a healing period of 3 weeks post-augmentation.

Interventions

Placement of a "Straumann® Bone Level Tapered implant SLActive®" (hydrophilic surface)

Immediately after tooth extraction, patients will receive a "Straumann® Bone Level Tapered SLActive®" mini-implant at the ideal prosthetic position of the final implant, and bone augmentation using bone graft "maxgraft® " and dental membrane "collprotect®membrane".

The mini-implant will be removed as a core trephine biopsy; the resulting osteotomies will be fine-prepared, and the final permanent implant will be placed after a healing period of 3 weeks post-augmentation.

Intervention Type: DEVICE

Placement of a "Straumann® Bone Level Tapered implant SLA®" (hydrophobic surface)

Immediately after tooth extraction, patients will receive a "Straumann® Bone Level Tapered SLA®" mini-implant at the ideal prosthetic position of the final implant, and bone augmentation using bone graft "maxgraft® " and dental membrane "collprotect®membrane".

The mini-implant will be removed as a core trephine biopsy; the resulting osteotomies will be fine-prepared, and the final permanent implant will be placed after a healing period of 3 weeks post-augmentation.

Intervention Type: DEVICE

Eligibility Criteria

Inclusion Criteria

• Patient age ≥ 18 years
• Patients with a diagnosed indication for single tooth extraction and scheduled for consented replacement by an implant-based restoration requiring prior bone augmentation
• Only patients displaying periodontally healthy teeth adjacent to the extracted teeth shall be included (probing depth (PD) < 4mm, no bleeding on probing (BOP)
• Patients must be physically and psychologically able to undergo implant surgery and restorative procedures (American Academy of Anesthesiologist class I or II)

Exclusion Criteria

• Presence of any general contra-indication related to implant therapy
• Heavy smokers ( ≥10 cigarettes/day)
• Patients displaying a history of uncontrolled metabolic disorders (e.g. diabetes mellitus)
• Patients with a history of malignancy, radiotherapy, or chemotherapy
• Pregnant or breast feeding patients
• Patients with a history of immunodeficiencies
• Patients displaying any metabolic bone disease
• Patients with disturbed bone or wound healing
• Patients with untreated or active periodontitis (BOP and PD>5mm)
• Extraction sites displaying an absent or defections buccal bone plate
• Vulnerable patients will be excluded from the study.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

University Hospital, Geneva

OTHER

Sponsor Role: lead

Responsible Party

Alexandre Perez

Head of Oral surgery and implantology unit

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Alexandre Perez, Dr

Role: PRINCIPAL_INVESTIGATOR

University of Geneva

Central Contacts

Alexandre Perez, Dr

Role: CONTACT

alexandre.perez@hug.ch

+4179 553 50 41

Other Identifiers

AP2022-06

Identifier Type: -

Identifier Source: org_study_id